194 related articles for article (PubMed ID: 16984371)
1. Personalized peptide vaccines: a new therapeutic modality for cancer.
Itoh K; Yamada A
Cancer Sci; 2006 Oct; 97(10):970-6. PubMed ID: 16984371
[TBL] [Abstract][Full Text] [Related]
2. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
3. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.
Uemura H; Fujimoto K; Mine T; Uejima S; de Velasco MA; Hirao Y; Komatsu N; Yamada A; Itoh K
Cancer Sci; 2010 Mar; 101(3):601-8. PubMed ID: 20128819
[TBL] [Abstract][Full Text] [Related]
4. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
Noguchi M; Itoh K; Yao A; Mine T; Yamada A; Obata Y; Furuta M; Harada M; Suekane S; Matsuoka K
Prostate; 2005 Apr; 63(1):1-12. PubMed ID: 15378520
[TBL] [Abstract][Full Text] [Related]
5. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
6. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
Sato Y; Fujiwara T; Mine T; Shomura H; Homma S; Maeda Y; Tokunaga N; Ikeda Y; Ishihara Y; Yamada A; Tanaka N; Itoh K; Harada M; Todo S
Cancer Sci; 2007 Jul; 98(7):1113-9. PubMed ID: 17459063
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
Naito M; Itoh K; Komatsu N; Yamashita Y; Shirakusa T; Yamada A; Moriya F; Ayatuka H; Mohamed ER; Matsuoka K; Noguchi M
Prostate; 2008 Dec; 68(16):1753-62. PubMed ID: 18767041
[TBL] [Abstract][Full Text] [Related]
8. [Peptide-based cancer vaccine therapy for prostate cancer, bladder cancer, and malignant glioma].
Yamada A
Nihon Rinsho; 2011 Sep; 69(9):1657-61. PubMed ID: 21922770
[TBL] [Abstract][Full Text] [Related]
9. A new era in anticancer peptide vaccines.
Perez SA; von Hofe E; Kallinteris NL; Gritzapis AD; Peoples GE; Papamichail M; Baxevanis CN
Cancer; 2010 May; 116(9):2071-80. PubMed ID: 20187092
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
[TBL] [Abstract][Full Text] [Related]
11. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
12. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in cancer vaccines: an overview.
Itoh K; Yamada A; Mine T; Noguchi M
Jpn J Clin Oncol; 2009 Feb; 39(2):73-80. PubMed ID: 19015149
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles.
Yutani S; Komatsu N; Shichijo S; Yoshida K; Takedatsu H; Itou M; Kuromatu R; Ide T; Tanaka M; Sata M; Yamada A; Itoh K
Cancer Sci; 2009 Oct; 100(10):1935-42. PubMed ID: 19604246
[TBL] [Abstract][Full Text] [Related]
16. Multipeptide vaccination in cancer patients.
Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
[TBL] [Abstract][Full Text] [Related]
17. PSA-based vaccines for the treatment of prostate cancer.
Madan RA; Gulley JL; Arlen PM
Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
[TBL] [Abstract][Full Text] [Related]
18. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
19. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
Yamamoto K; Mine T; Katagiri K; Suzuki N; Kawaoka T; Ueno T; Matsueda S; Yamada A; Itoh K; Yamana H; Oka M
Oncol Rep; 2005 May; 13(5):874-83. PubMed ID: 15809753
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]